Ximing Bio completes $100M Series B as AI drug discovery enters the 'biological foundation model' era

AI drug discovery company Aureka Biotechnologies announced the completion of a $100 million Series B round, bringing its total funding to nearly $200 million. This comes just over three months after its previous $35 million Series A+ round.